SRRK

Scholar Rock Holding Corp. 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Scholar Rock Holding Corp. is a global biopharmaceutical company focused on developing monoclonal antibodies that target growth factors for neuromuscular diseases, cancer, and other conditions. The company has no commercial product revenue and relies on equity and debt financing to fund operations. The primary asset is apitegromab, a myostatin inhibitor for Spinal Muscular Atrophy (SMA), which is currently awaiting regulatory resubmission following a Complete Response Letter (CRL) from the FDA.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Surge: Total operating expenses increased by 59.8% in Q3 2025 compared to Q3 2024. General and Administrative (G&A) expenses spiked 230.4% (from $16.1M to $53.1M) due to investments in commercial infrastructure, increased headcount, and professional fees.
• Regulatory Setback: In September 2025, the FDA issued a CRL for the apitegromab Biologics License Application (BLA). The delay is attributed to observations at a third-party fill-finish facility (Form 483, "Official Action Indicated"), not the drug's efficacy or safety data.
• Debt Financing: The company received an additional $50.0 million tranche under its amended loan agreement in September 2025, bringing total outstanding term loans to $100.0 million.
• Equity Raises: The company generated $91.7 million in net proceeds from the sale of common shares under its At-The-Market (ATM) program during the nine months ended September 30, 2025.

Guidance, Outlook, and Risks

• Regulatory Path: The company plans to resubmit the apitegromab BLA once the third-party facility is reclassified by the FDA. A constructive Type A meeting with the FDA was completed in November 2025. The European Medicines Agency (EMA) marketing authorization application (MAA) remains under review.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($369.6 million) are sufficient to fund operations into 2027. However, additional capital will be required to complete clinical development and commercialization.
• Key Risks:
  • Manufacturing: Reliance on a single third-party fill-finish facility which currently has an "Official Action Indicated" status.
  • Capital Needs: Continued significant operating losses and the need for future financing to fund commercialization and pipeline development.
  • Regulatory Uncertainty: Potential delays in FDA review due to government staffing changes or policy shifts.
• Pipeline Updates:
  • SRK-439: IND cleared by FDA; Phase 1 dosing in healthy volunteers planned for Q4 2025.
  • SRK-181: Phase 1 DRAGON trial completed in June 2025 with encouraging responses in anti-PD-(L)1 resistant cancers.
  • Apitegromab (Obesity): Phase 2 EMBRAZE trial showed 54.9% preservation of lean mass when combined with tirzepatide.

Investor Verification Checklist

• Verify the timeline for the reclassification of the third-party fill-finish facility by the FDA to assess the resubmission date for the apitegromab BLA.
• Monitor the burn rate and cash runway, specifically the impact of the 230% increase in G&A expenses on the projected 2027 liquidity horizon.
• Review the terms of the amended loan agreement with Oxford Finance, specifically the milestones required to access the remaining $100 million in tranches.
• Assess the progress of the Phase 2 OPAL trial in SMA patients under two years of age, initiated in Q3 2025.
• Confirm the status of the EMA MAA review process for apitegromab as a potential alternative or parallel approval pathway.